110 related articles for article (PubMed ID: 28866062)
1. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
Jiang T; Du J; Raynald ; Wang J; Li C
World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
[TBL] [Abstract][Full Text] [Related]
2. Isolated subependymal giant cell astrocytoma (SEGA) in the absence of clinical tuberous sclerosis: two case reports and literature review.
Cobourn KD; Chesney KM; Mueller K; Fayed I; Tsering D; Keating RF
Childs Nerv Syst; 2024 Jan; 40(1):73-78. PubMed ID: 37658938
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytomas Treated with Laser Interstitial Thermal Therapy, Open Surgical Resection, and mTOR Inhibitors.
Boop S; Bonda D; Randle S; Leary S; Vitanza N; Crotty E; Novotny E; Friedman S; Ellenbogen RG; Durfy S; Goldstein H; Ojemann JG; Hauptman JS
Pediatr Neurosurg; 2023; 58(3):150-159. PubMed ID: 37232001
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Therapy with Everolimus for Subependymal Giant Cell Astrocytoma: A Case Report.
Karita H; Tsuda K; Kono M; Yamamoto T; Ihara S
NMC Case Rep J; 2023; 10():291-297. PubMed ID: 37953906
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
[TBL] [Abstract][Full Text] [Related]
7. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
[TBL] [Abstract][Full Text] [Related]
8. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
[TBL] [Abstract][Full Text] [Related]
9. Sporadic subependymal giant cell astrocytoma with somatic
Alassiri AH; Alfayea TM; Aljared TI; Alenezi KR
Neurosciences (Riyadh); 2024 May; 29(2):139-143. PubMed ID: 38740392
[TBL] [Abstract][Full Text] [Related]
10. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.
Krueger DA; Care MM; Agricola K; Tudor C; Mays M; Franz DN
Neurology; 2013 Feb; 80(6):574-80. PubMed ID: 23325902
[TBL] [Abstract][Full Text] [Related]
11. Subependymal Giant Cell Astrocytoma Tumors in Patients Without Clinical Manifestation of Tuberous Sclerosis Complex: A Diagnostic Puzzle.
Zabielska B; Rzewuska N; Jóźwiak S
Pediatr Neurol; 2024 Jan; 150():40-42. PubMed ID: 37951161
[No Abstract] [Full Text] [Related]
12. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
[TBL] [Abstract][Full Text] [Related]
13. An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients.
Liu M; Ye J; You X
Childs Nerv Syst; 2024 Mar; 40(3):823-829. PubMed ID: 37906297
[TBL] [Abstract][Full Text] [Related]
14. Subependymal giant-cell astrocytomas in the absence of tuberous sclerosis.
Reynolds RA; Aum DJ; Gonzalez-Gomez I; Wong M; Roberts K; Dahiya S; Rodriguez LF; Roland JL; Smyth MD
J Neurosurg Pediatr; 2023 Sep; 32(3):351-357. PubMed ID: 37327147
[TBL] [Abstract][Full Text] [Related]
15. Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Gau SY; Chen SL; Chang CS; Tsao TF; Tsai JD
Int J Med Sci; 2023; 20(10):1358-1362. PubMed ID: 37786437
[No Abstract] [Full Text] [Related]
16. mTOR Inhibitors in Tuberous Sclerosis Complex.
Curatolo P; Moavero R
Curr Neuropharmacol; 2012 Dec; 10(4):404-15. PubMed ID: 23730262
[TBL] [Abstract][Full Text] [Related]
17. Subependymal giant cell astrocytoma in the absence of tuberous sclerosis: illustrative case.
Shelley I; Mahtabfar A; Farrell CJ
J Neurosurg Case Lessons; 2023 Jun; 5(25):. PubMed ID: 37354433
[TBL] [Abstract][Full Text] [Related]
18. New Insights into Red Blood Cell Microcytosis upon mTOR Inhibitor Administration.
Jakubowska J; Pawlik B; Wyka K; Stolarska M; Kotulska K; Jóźwiak S; Młynarski W; Trelińska J
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202704
[TBL] [Abstract][Full Text] [Related]
19. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia.
Leitner DF; Kanshin E; Askenazi M; Siu Y; Friedman D; Devore S; Jones D; Ueberheide B; Wisniewski T; Devinsky O
PLoS One; 2022; 17(5):e0268597. PubMed ID: 35587487
[TBL] [Abstract][Full Text] [Related]
20. Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma.
Maász A; Bodó T; Till Á; Molnár G; Masszi G; Labossa G; Herbert Z; Bene J; Hadzsiev K
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
